- Docket Number:
- Issued by:
Guidance Issuing OfficeOffice of the Commissioner,Office of Policy, Legislation, and International Affairs,Office of Policy
Table of Contents
- To obtain copies of this guidance
On June 26, 2013, in United States v. Windsor, 133 S.Ct. 2675, the Supreme Court struck down as unconstitutional section 3 of the Defense of Marriage Act (DOMA). Using a question and answer format, we, FDA, are informing the public of our current thinking about the meaning of "spouse" or "family" in our regulations in light of this ruling.
FDA’s guidance documents, including this guidance, do not establish legally enforceable responsibilities. Instead, guidances describe the Agency’s current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited.
A1: Section 3 of DOMA defined "marriage" and "spouse" to exclude same-sex spouses. Because the Supreme Court ruled this section unconstitutional, FDA need no longer exclude same-sex spouses from the definition of these terms. Consistent with the Department of Health and Human Service (HHS) policy, FDA will interpret the terms "spouse" and "family" in its regulations to include same-sex spouses.
A2: No. We interpret "spouse" or "family" in our regulations to include any individuals of the same sex who are lawfully married and whose marriage is valid in the state, territory or foreign nation where it took place. These terms also include same-sex spouses whose marriages are valid in the state, territory, or foreign nation where they live. This policy is consistent with a post-Windsor policy of treating same-sex marriages on the same terms as opposite-sex marriages to the greatest extent reasonably possible. By broadening the coverage of "spouse" and "family" to include same-sex spouses, it also advances the underlying goals of FDA’s regulations. For example, requiring clinical investigators to disclose the financial interests and arrangements of their same-sex spouses (see discussion of FDA Financial Disclosure by Clinical Investigators below) better ensures that conflicts of interests do not arise.
A3: Because they use the terms "spouse" or "family," six parts of FDA’s regulations are affected by the Windsor decision. Consistent with this decision and HHS policy, FDA now reads these terms to include same-sex spouses. The affected regulations are as follows:
- FDA Freedom of Information Act (FOIA) program (21 CFR 20.44 (b)). A "family member," including a same-sex spouse, of an individual subject to an imminent threat may request expedited processing of a FOIA request.
- FDA Human Subject Protection (21 CFR 50.3 (l), (m), 50.24(a)(6), (a)(7)(v), (b)). "Family member" means, among other things, "spouse," "brothers, sisters, and spouses of brothers and sisters," and "any individual related by . . . affinity whose close association with the subject is the equivalent of a family relationship." An exception from the requirement to obtain informed consent of research subjects exists if obtaining informed consent is not feasible and a legally authorized representative is not reasonably available. If feasible, an investigator must attempt to contact a subject’s family member, which can include a same-sex spouse, to ask whether he or she objects to the subject’s participation in the clinical investigation. Additionally, if a subject remains incapacitated and a subject’s legally authorized representative is not reasonably available, an Institutional Review Board (IRB) shall ensure that there is a procedure to inform a family member, which can include a same-sex spouse, that he or she may discontinue the subject’s participation at any time without penalty or loss of benefits to which the subject is otherwise entitled. If such a family member is told about the clinical investigation and the subject’s condition improves, the subject is also to be informed as soon as feasible. If a subject is entered into a clinical investigation with waived consent and the subject dies before a legally authorized representative or family member, which can include a same-sex spouse, can be contacted, information about the clinical investigation is to be provided to the subject’s legally authorized representative or such family member, if feasible.
- FDA Financial Disclosure by Clinical Investigators (21 CFR 54.2(d)). Part 54 of FDA’s regulations requires disclosure of certain types of financial interests and arrangements involving a "clinical investigator" and defines "clinical investigator" to include the investigator’s "spouse." Consistent with the Windsor decision and HHS policy, FDA now interprets Part 54 to require disclosure of certain financial interests and arrangements involving any clinical investigator’s same-sex spouse.
- Institutional Review Board for FDA-regulated Research (21 CFR 56.107(d)). Each IRB must have at least one member who is not otherwise affiliated with the institution and is not part of the "immediate family," now including a same-sex spouse, of a person affiliated with the institution.
- Qualified Expert Panels for Indexing New Animal Drugs (21 CFR 516.141(g)(2), (g)(3)). Information required to be submitted to FDA and factors considered to prevent conflicts of interest in members of these expert panels include information relating to "spouses," including same-sex spouses.
- Mammography Quality Standards Program (21 CFR 900.2(k)). Mammography facilities must have systems for collecting and resolving consumer complaints. "Consumer" includes a patient or patient representative—for example, a "family member," including a same-sex spouse.
- Additional copies of this guidance are available from the Office of Policy, Office of the Commissioner, Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD 20993, or by calling 301-796-4830,
You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))
If unable to submit comments online, please mail written comments to:
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852
All written comments should be identified with this document's docket number: FDA-2014-D-0261.